Inflammation  >>  INO-8000  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
INO-8000 / Inovio
VGX-6150-01, NCT02027116: Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection

Completed
1
18
RoW
VGX-6150
GeneOne Life Science, Inc., Inovio Pharmaceuticals
Hepatitis C, Chronic
07/15
07/17
NCT02822079: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

Recruiting
1
32
US
DNA Plasmid Encoding Interleukin-12 INO-9012, INO-9012, Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, INO-8000, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment
Mayo Clinic, Inovio Pharmaceuticals, National Cancer Institute (NCI)
Chronic Hepatitis, Hepatitis C Infection
03/20
 
NCT02772003: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

Active, not recruiting
1
33
US
Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, INO-8000, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Rocakinogene Sifuplasmid, DNA Plasmid Encoding Interleukin-12 INO-9012, INO-9012
National Cancer Institute (NCI), Inovio Pharmaceuticals
Chronic Hepatitis, Hepatitis C Infection
03/20
03/25

Download Options